Samuel George A. III 4

What Happened

• Samuel George A. III, General Counsel and Secretary of Lineage Cell Therapeutics (LCTX), was granted 900,000 derivative shares reported as an award on March 5, 2026. The filing shows an acquisition at $0.00 (no cash paid at grant) and identifies the award as options in the footnote. Total reported value at grant is $0 on the Form 4 (grant is compensation, not an open-market purchase).

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 6, 2026 (timely filing).
• Reported transaction: Award/Grant (derivative) of 900,000 shares at $0.00.
• Shares owned following the transaction: not specified in the filing.
• Footnote (F1): One quarter of the options vests on March 5, 2027; the remaining options vest in 36 monthly installments thereafter, contingent on continued employment.
• No immediate sale or cashless exercise reported; this is a standard compensation grant, not a purchase or sale.

Context

• This was a compensation award of derivative securities (options) with a 1‑year cliff (25% after one year) followed by monthly vesting over three years — common for executive equity incentives. Because no exercise or sale occurred, there is no immediate market impact from this filing; it reflects future potential ownership subject to vesting and any exercise terms.